RU2014103543A - Ботулотоксины для применения в способе лечения жировых отложений - Google Patents

Ботулотоксины для применения в способе лечения жировых отложений Download PDF

Info

Publication number
RU2014103543A
RU2014103543A RU2014103543/15A RU2014103543A RU2014103543A RU 2014103543 A RU2014103543 A RU 2014103543A RU 2014103543/15 A RU2014103543/15 A RU 2014103543/15A RU 2014103543 A RU2014103543 A RU 2014103543A RU 2014103543 A RU2014103543 A RU 2014103543A
Authority
RU
Russia
Prior art keywords
botulinum
type
composition contains
patient
treatment
Prior art date
Application number
RU2014103543/15A
Other languages
English (en)
Russian (ru)
Inventor
Кэтрин СЕРНОК
Кеннет МАРТИНЕЗ
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2014103543A publication Critical patent/RU2014103543A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RU2014103543/15A 2011-07-20 2012-07-19 Ботулотоксины для применения в способе лечения жировых отложений RU2014103543A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509700P 2011-07-20 2011-07-20
US61/509,700 2011-07-20
PCT/US2012/047405 WO2013013042A1 (en) 2011-07-20 2012-07-19 Botulinum toxins for use in a method for treatment of adipose deposits

Publications (1)

Publication Number Publication Date
RU2014103543A true RU2014103543A (ru) 2015-08-27

Family

ID=46601917

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014103543/15A RU2014103543A (ru) 2011-07-20 2012-07-19 Ботулотоксины для применения в способе лечения жировых отложений

Country Status (12)

Country Link
US (1) US20140127188A1 (en:Method)
EP (1) EP2734224A1 (en:Method)
JP (1) JP2014520892A (en:Method)
KR (1) KR20140082956A (en:Method)
CN (1) CN103702681A (en:Method)
AU (1) AU2012283968B2 (en:Method)
BR (1) BR112014001066A2 (en:Method)
CA (1) CA2841955A1 (en:Method)
IN (1) IN2014DN00254A (en:Method)
MX (1) MX2014000612A (en:Method)
RU (1) RU2014103543A (en:Method)
WO (1) WO2013013042A1 (en:Method)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9655926B1 (en) 2013-08-23 2017-05-23 Amiya Prasad Treatment for hair thinning and hair loss
US9884001B2 (en) * 2014-08-07 2018-02-06 Sang Duck Kim Botulinum toxin in aerosol form and method of facial contouring using the same
WO2017106625A1 (en) 2015-12-18 2017-06-22 Dow Corning Corporation High purity trisilylamine, methods of making, and use
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
RU2019141383A (ru) * 2017-05-18 2021-06-18 Реванс Терапьютикс, Инк. (Revance Therapeutics, Inc.) Способы лечения цервикальной дистонии
US20190030118A1 (en) * 2017-07-27 2019-01-31 Ipsen Biopharm Limited Treatment of lower limb spasticity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP1086702B1 (en) 1994-05-09 2005-04-13 BINDER, William J. Presynaptic neurotoxins for treatment of migraine headache
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
PT1658858E (pt) 1997-07-15 2010-02-26 Univ Colorado Utilização de toxina botulínica para o tratamento da disfunção urinária recalcitrante
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
EP1545207B1 (en) * 2002-08-19 2018-03-14 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
SG10201400339VA (en) * 2004-03-03 2014-05-29 Revance Therapeutics Inc Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US7727537B2 (en) * 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
PL3295955T3 (pl) * 2005-12-01 2021-10-25 University Of Massachusetts Lowell Nanoemulsje botulinowe
US20110177140A1 (en) * 2007-08-31 2011-07-21 Rainer Voegeli 4-amidino benzylamines for cosmetic and/or dermatological use
US20090297632A1 (en) * 2008-06-02 2009-12-03 Waugh Jacob M Device, Methods and Compositions to Alter Light Interplay with Skin
CN102076333A (zh) * 2008-06-26 2011-05-25 安特里奥公司 真皮递送
RU2530629C2 (ru) * 2009-03-02 2014-10-10 Дорис ЭКСЕЛ Вызываемая медикаментозными средствами липоатрофия для косметических целей

Also Published As

Publication number Publication date
CN103702681A (zh) 2014-04-02
JP2014520892A (ja) 2014-08-25
WO2013013042A1 (en) 2013-01-24
KR20140082956A (ko) 2014-07-03
IN2014DN00254A (en:Method) 2015-06-05
CA2841955A1 (en) 2013-01-24
US20140127188A1 (en) 2014-05-08
AU2012283968A1 (en) 2014-02-06
AU2012283968B2 (en) 2016-04-14
MX2014000612A (es) 2014-02-27
EP2734224A1 (en) 2014-05-28
BR112014001066A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
RU2014103543A (ru) Ботулотоксины для применения в способе лечения жировых отложений
EA201791199A1 (ru) Способ лечения болезни альцгеймера
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
RU2013136378A (ru) Применение фитоканнабиноида каннабидиола(cbd) в комбинации со стандартным противоэпилептическим стедством(saed) для лечения эпилепсии
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
MX392388B (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe)
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
NZ720273A (en) Preparations and methods for treating a gd2 positive cancer
JP2013520447A5 (en:Method)
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
RU2015155001A (ru) Диагностика и лечение болезни альцгеймера с использованием аннексинов, меченных радионуклидом
RU2010133699A (ru) Способ комбинированного лечения глаукомной оптической нейропатии
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
UA115940U (uk) Спосіб лікування локального і загального жирового відкладення
RU2012144929A (ru) Способ лечения больных с миофасциальным болевым дисфункциональным синдромом

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170510